Cargando…

Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

BACKGROUND: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Takayuki, Tomomatsu, Jyunichi, Fukada, Ippei, Shibayama, Tomoko, Teruya, Natsuki, Ito, Yoshinori, Iwase, Takuji, Ohno, Shinji, Takahashi, Shunji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4936231/ https://www.ncbi.nlm.nih.gov/pubmed/27389013 http://dx.doi.org/10.1186/s12885-016-2436-5

Ejemplares similares

Imatinib could be a new strategy for pulmonary hypertension caused by pulmonary tumor thrombotic microangiopathy in metastatic breast cancer
por: Fukada, Ippei, et al.
Publicado: (2016)

The early onset of peripheral neuropathy might be a robust predictor for time to treatment failure in patients with metastatic breast cancer receiving chemotherapy containing paclitaxel
por: Fukada, Ippei, et al.
Publicado: (2017)

Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review
por: Yokoe, Takamichi, et al.
Publicado: (2017)

Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer
por: Fukada, Ippei, et al.
Publicado: (2016)

Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine
por: Fukuda, Takayo, et al.
Publicado: (2015)

A Case of Recurrent Breast Cancer Identified by Pulmonary Tumor Thrombotic Microangiopathy
por: Abe, Tomomi, et al.
Publicado: (2017)

Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis
por: Inari, Hitoshi, et al.
Publicado: (2020)

Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy
por: Inari, Hitoshi, et al.
Publicado: (2020)

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer
por: Chin, Yoon Ming, et al.
Publicado: (2022)

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
por: Araki, Kazuhiro, et al.
Publicado: (2018)

MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer
por: Inagaki, Lina, et al.
Publicado: (2021)

Intratumoral heterogeneity, treatment response, and survival outcome of ER‐positive HER2‐positive breast cancer
por: Teruya, Natsuki, et al.
Publicado: (2023)

Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype
por: Fukuda, Takayo, et al.
Publicado: (2016)

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
por: Fukada, Ippei, et al.
Publicado: (2021)

Assessment of a cancer genomic profile test for patients with metastatic breast cancer
por: Fukada, Ippei, et al.
Publicado: (2022)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
por: Watanabe, Junichiro, et al.
Publicado: (2017)

Decreased hormonal sensitivity after childbirth rather than the tumor size influences the prognosis of very young breast cancer patients
por: Makita, Masujiro, et al.
Publicado: (2015)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
por: Takahashi, Shunji, et al.
Publicado: (2016)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Changes in Treatment Behavior during the COVID-19 Pandemic among Patients at a Cancer Hospital
por: Sato, Yasuyoshi, et al.
Publicado: (2021)

Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype
por: Maeshima, Yurina, et al.
Publicado: (2021)

Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era
por: Nakajima, Naomi, et al.
Publicado: (2018)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a80n6a1lgbvtb6sqlnt9p5v0em